Earnings Call · Q4 FY2022·2023-02-28

Q4 22EPS -100.00%·Rev n/aQ3 22EPS +100.00%*·Rev n/aQ2 22EPS +3.95%·Rev n/aQ1 22EPS +67.16%·Rev n/a⚠ consensus missing

ADC Therapeutics SA ADCT

Amanda Hamilton — Investor Relations or Corporate Communications

Ameet Mallik — Chief Executive Officer

Kristen Harrington-Smith — Commercial Leader (likely Head of Commercial or similar)

Mohamed Zaki — Chief Medical Officer or Head of Clinical Development

Pepe Carmona — Chief Financial Officer

−11.5%1d on move date−11.2% vs SPY3d−19.7%5d−28.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ADCT calls or request research access.

More ADCT calls Browse calls Request research access